PDCD1 and Hodgkins lymphoma: Two other women (39 years old, Hodgkin’s lymphoma, and 38 years old, malignant melanoma) reported spontaneous abortion about one year and two years after the end of anti-PD-1 monotherapy with nivolumab and pembrolizumab, respectively.